Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

Phase 1/2 Completed 171 enrolled Beech Tree Labs, Inc. Norwich Clinical Research Associates Ltd. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.

Timeline

Start: 2011-01
Primary completion: 2012-10
Completion: 2012-11

Outcome

Missed primary endpoint

paper Progression to lesion post-dental procedure was prevented in 54.5% (12/22) TML subjects versus 22.2% (2/9) control subjects (p = 0.106). PMID 35142535 ↗

paper CONCLUSIONS: Neither clinical trial showed a statistically significant effect of BTL-TML on progression to lesion. PMID 35142535 ↗

Publications

Mamber SW, Hatch T, Miller CS, Murray JV, Strout C, McMichael J. Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis. J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X221078004. doi: 10.1177/2515690X221078004.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Thimerosal	Small molecule	—	Other